bioAffinity Technologies, Inc.

bioAffinity Technologies reported a net loss of $14.9 million for FY 2025, a significant increase from a $9.0 million loss in FY 2024, despite raising $16.9 million in gross proceeds from equity transactions. Consolidated revenue decreased 34% to $6.2 million from $9.4 million, primarily due to strategic actions to discontinue unprofitable pathology services and improve operating focus. However, CyPath Lung testing revenue grew 87% to $963,000, driven by a 99% increase in test results delivered. The company ended the year with $6.4 million in cash and cash equivalents, but management anticipates cash resources are sufficient only through June 2026, raising substantial doubt about its ability to continue as a going concern without additional financing.

Key Takeaways